Ryman Healthcare Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Ryman Healthcare wird ein jährliches Gewinn- und Umsatzwachstum von 22.6% bzw. 9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6.6% betragen.

Wichtige Informationen

22.6%

Wachstumsrate der Gewinne

18.8%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	10.5%
Wachstumsrate der Einnahmen	9.0%
Zukünftige Eigenkapitalrendite	6.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Ryman Healthcare Limited (NZSE:RYM) Shares Could Be 24% Below Their Intrinsic Value Estimate

May 30

Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

Aug 26

When Should You Buy Ryman Healthcare Limited (NZSE:RYM)?

May 04

What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Jan 08

Investors Could Be Concerned With Ryman Healthcare's (NZSE:RYM) Returns On Capital

Oct 14

Is It Too Late To Consider Buying Ryman Healthcare Limited (NZSE:RYM)?

Sep 14

Is Ryman Healthcare (NZSE:RYM) Using Too Much Debt?

Aug 04

Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

May 22

Is Ryman Healthcare Limited (NZSE:RYM) A Good Fit For Your Dividend Portfolio?

Apr 17

Should You Review Recent Insider Transactions At Ryman Healthcare Limited (NZSE:RYM)?

Mar 20

Our Take On The Returns On Capital At Ryman Healthcare (NZSE:RYM)

Mar 07

Do Institutions Own Ryman Healthcare Limited (NZSE:RYM) Shares?

Feb 23

Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint An Interesting Picture

Nov 23

Gewinn- und Umsatzwachstumsprognosen

NZSE:RYM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (NZD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	893	476	112	601	2
3/31/2026	824	396	331	708	2
3/31/2025	750	555	-251	597	2
3/31/2024	688	5	379	658	N/A
12/31/2023	658	128	362	697	N/A
9/30/2023	617	251	365	745	N/A
6/30/2023	593	254	292	698	N/A
3/31/2023	582	258	199	642	N/A
12/31/2022	558	432	139	585	N/A
9/30/2022	535	605	80	529	N/A
6/30/2022	522	649	158	557	N/A
3/31/2022	509	693	237	586	N/A
12/31/2021	495	593	291	602	N/A
9/30/2021	481	492	345	618	N/A
6/30/2021	469	458	246	515	N/A
3/31/2021	456	423	147	413	N/A
12/31/2020	447	356	104	352	N/A
9/30/2020	438	289	60	290	N/A
6/30/2020	431	277	100	370	N/A
3/31/2020	423	265	140	450	N/A
12/31/2019	413	305	148	445	N/A
9/30/2019	402	345	155	440	N/A
6/30/2019	392	335	184	421	N/A
3/31/2019	382	326	213	401	N/A
12/31/2018	373	341	200	397	N/A
9/30/2018	364	355	188	392	N/A
6/30/2018	353	372	164	371	N/A
3/31/2018	342	388	141	349	N/A
12/31/2017	329	380	N/A	343	N/A
9/30/2017	315	372	N/A	337	N/A
6/30/2017	302	365	N/A	330	N/A
3/31/2017	289	357	N/A	323	N/A
12/31/2016	281	358	N/A	320	N/A
9/30/2016	273	360	N/A	316	N/A
6/30/2016	266	333	N/A	314	N/A
3/31/2016	260	305	N/A	312	N/A
12/31/2015	252	286	N/A	294	N/A
9/30/2015	244	267	N/A	276	N/A
6/30/2015	235	254	N/A	255	N/A
3/31/2015	226	242	N/A	234	N/A
12/31/2014	219	233	N/A	236	N/A
9/30/2014	212	224	N/A	237	N/A
6/30/2014	207	210	N/A	238	N/A
3/31/2014	203	195	N/A	238	N/A
12/31/2013	197	171	N/A	234	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RYMDas prognostizierte Gewinnwachstum (22.6% pro Jahr) liegt über der Sparquote (3%).

Ertrag vs. Markt: RYMDie Erträge des Unternehmens (22.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt NZ (24.5% pro Jahr).

Hohe Wachstumserträge: RYMEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: RYMDie Einnahmen des Unternehmens (9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt NZ (4.2% pro Jahr).

Hohe Wachstumseinnahmen: RYMDie Einnahmen des Unternehmens (9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RYMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (6.6%).

Ryman Healthcare Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 30%

Price target decreased by 17% to NZ$6.05

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 22%

Price target decreased by 7.5% to NZ$7.50

Consensus EPS estimates fall by 37%

Recent updates

Consensus EPS estimates increase by 30%

Ryman Healthcare Limited to Report First Half, 2025 Results on Nov 28, 2024

Is Ryman Healthcare (NZSE:RYM) Weighed On By Its Debt Load?

Insider recently sold NZ$612k worth of stock

Are Investors Undervaluing Ryman Healthcare Limited (NZSE:RYM) By 47%?

Ryman Healthcare Limited, Annual General Meeting, Aug 01, 2024

Ryman Healthcare's (NZSE:RYM) Soft Earnings Don't Show The Whole Picture

Price target decreased by 17% to NZ$6.05

New major risk - Financial position

Full year 2024 earnings released: EPS: NZ$0.007 (vs NZ$0.50 in FY 2023)

Little Excitement Around Ryman Healthcare Limited's (NZSE:RYM) Earnings

Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint A Concerning Picture

Ryman Healthcare Limited to Report Fiscal Year 2024 Results on May 27, 2024

Investor sentiment deteriorates as stock falls 17%

Ryman Healthcare Limited's (NZSE:RYM) P/E Is On The Mark

Here's Why Ryman Healthcare (NZSE:RYM) Has A Meaningful Debt Burden

Capital Allocation Trends At Ryman Healthcare (NZSE:RYM) Aren't Ideal

First half 2024 earnings released: EPS: NZ$0.27 (vs NZ$0.39 in 1H 2023)

Consensus EPS estimates fall by 12%

Ryman Healthcare Limited to Report First Half, 2024 Results on Nov 29, 2023

What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Less than half of directors are independent

Ryman Healthcare (NZSE:RYM) Has Debt But No Earnings; Should You Worry?

Ryman Healthcare Limited, Annual General Meeting, Jul 27, 2023

Consensus EPS estimates increase by 22%

Ryman Healthcare Limited (NZSE:RYM) Shares Could Be 24% Below Their Intrinsic Value Estimate

Ryman Healthcare Limited to Report Fiscal Year 2023 Results on May 19, 2023

Price target decreased by 7.5% to NZ$7.50

Consensus EPS estimates fall by 37%

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 17% to NZ$8.69

Price target decreased by 8.0% to NZ$9.82

Price target decreased by 7.8% to NZ$10.36

Investor sentiment improves as stock rises 15%

Insufficient new directors

Upcoming dividend of NZ$0.088 per share

Consensus forecasts updated

Investor sentiment deteriorated over the past week

First half 2023 earnings released: EPS: NZ$0.39 (vs NZ$0.56 in 1H 2022)

Ryman Healthcare Limited Announces Interim Dividend, Payable on December 16, 2022

Ryman Healthcare Limited to Report Q2, 2023 Results on Nov 18, 2022

Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

Ryman Healthcare Appoints Cheyne Chalmers as New Zealand CEO

Consensus revenue estimates increase by 15%

Full year 2022 earnings: Revenues exceed analyst expectations

Ryman Healthcare Limited, Annual General Meeting, Jul 28, 2022

Ryman Healthcare Limited to Report Fiscal Year 2022 Results on May 20, 2022

When Should You Buy Ryman Healthcare Limited (NZSE:RYM)?

Consensus forecasts updated

Now 21% undervalued after recent price drop

Consensus forecasts updated

What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Independent Non-Executive Director recently bought NZ$99k worth of stock

Upcoming dividend of NZ$0.088 per share

Key Executive recently bought NZ$194k worth of stock

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Could Be Concerned With Ryman Healthcare's (NZSE:RYM) Returns On Capital

Is It Too Late To Consider Buying Ryman Healthcare Limited (NZSE:RYM)?

Is Ryman Healthcare (NZSE:RYM) Using Too Much Debt?

Full year 2021 earnings released: EPS NZ$0.85 (vs NZ$0.53 in FY 2020)

Independent Director recently bought NZ$297k worth of stock

Upcoming dividend of NZ$0.14 per share

Ryman Healthcare Limited Declares Final Dividend, Payable June 18 2021

Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

Full year 2021 earnings released: EPS NZ$0.85 (vs NZ$0.53 in FY 2020)

Is Ryman Healthcare Limited (NZSE:RYM) A Good Fit For Your Dividend Portfolio?

Should You Review Recent Insider Transactions At Ryman Healthcare Limited (NZSE:RYM)?

Our Take On The Returns On Capital At Ryman Healthcare (NZSE:RYM)

Ryman Healthcare Limited Announces Executive Changes